Interferon beta-1a biosimilar - Reliance Life Sciences

Drug Profile

Interferon beta-1a biosimilar - Reliance Life Sciences

Alternative Names: R-TPR-011; ReliBeta

Latest Information Update: 07 May 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Reliance Life Sciences
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 01 Oct 2011 Launched for Multiple sclerosis in India (IM) - First global launch
  • 23 Sep 2011 Reliance Life Sciences completes a phase III trial in Multiple sclerosis in India (CTRI/2009/091/000655)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top